← Back to Search

Hsp90 Inhibitor

PU-H71 for Lymphoma

Phase 1
Waitlist Available
Led By Komal Jhaveri, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Prior therapy for advanced malignancy with no current curative option
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new drug, called PU-H71, to find out what effects it has on patients and cancer cells. PU-H71 blocks a protein called Heat Shock Protein-90 (Hsp90). Hsp90 is found in both normal and cancer cells, but may be more important in cancer cells. Attacking Hsp90 can stop the function of certain proteins that are needed for cancer cells to survive.

Eligible Conditions
  • Myeloproliferative Neoplasms
  • Metastatic Tumor
  • Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You have received treatment for advanced cancer, but there is no cure available at this time.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To assess the pharmacokinetics of PU-H71 in patients with advanced malignancies.
To assess the safety of PU-H71 in patients with advanced malignancies.
To assess the tolerability of PU-H71 in patients with advanced malignancies.
+1 more
Secondary outcome measures
To assess anti-tumor activity as defined by response rate
To evaluate 124I-PU-H71 as a non-invasive means to determine tumor pharmacokinetics and intra-tumoral concentration

Trial Design

1Treatment groups
Experimental Treatment
Group I: PU-H71Experimental Treatment1 Intervention
This Phase 1 trial will be an open-label, dose-escalation study of single-agent PU-H71 in patients with advanced solid malignancies and lymphoma.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PU-H71
2017
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,928 Previous Clinical Trials
591,761 Total Patients Enrolled
154 Trials studying Lymphoma
8,661 Patients Enrolled for Lymphoma
Komal Jhaveri, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does PU-H71 pose any potential risks to patients?

"Our team at Power evaluated PU-H71's safety and assigned it a score of 1 due to the paucity of evidence from Phase 1 trials that support its efficacy or security."

Answered by AI

Are there any related studies to PU-H71 that have already been conducted?

"Presently, there are 2 active trials for PU-H71; neither of which is in Phase 3. Both studies are situated in the city of New york and require patients to enroll at participating sites."

Answered by AI

What is the aggregate enrollment for this trial?

"Presently, this particular trial is not enrolling patients. The original announcement was made on July 1st 2011 and the most recent update occurred June 8th 2022. If you are seeking out other studies related to lymphoma, there are currently 3999 clinical trials actively recruiting participants as well as 2 specific to PU-H71."

Answered by AI

Are there vacancies available for individuals interested in participating in this research?

"Sadly, this medical trial is no longer taking on participants. It was first posted in July 2011 and its most recent update occurred on June 8th 2022. However, if you are looking for other studies to join there are 3999 trials involving lymphoma and two PU-H71 clinical studies actively recruiting volunteers."

Answered by AI
~3 spots leftby Mar 2025